Tagged with Generic

Taiwan Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s leadership in Taiwan and China and accelerate the group’s market penetration in strategic countries such as Japan and the US,…

Taiwan Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s leadership in Taiwan and China and accelerate the group’s market penetration in strategic countries such as Japan and the US,…

Switzerland The Chief Scientific Officer and President of Glenmark Pharmaceuticals Swiss R&D Center elaborates on Glenmark’s endeavor to venture up the pharmaceutical value chain and discusses the company’s R&D strategy. Furthermore, he highlights the significance of strategic partnerships in today’s pharmaceutical R&D efforts. You have spent 23 years working in large…

Greece The management team of PharOS discuss the company’s move from generics consultancy to co-developer, surviving in the Greek market, and internationalization plans. Founded back in 2002, PharOS has gained a formidable reputation as a pharma development company for bringing best in class generics products to market and prolonging their life…

Taiwan Petar Vazharov, Alvogen’s executive vice president for Asia Pacific, and, Jefferson Wang, general manager of Lotus, provide insights into Lotus’ tremendous evolution from a local generics company into a regional player holding international ambitions, and highlight the main achievements of this fast-growing company since it joined the Alvogen group in…

Greece John Bouros CEO and founder of Alvion Pharmaceuticals in Greece on the opportunities inherent in any economic crisis, the growth of the Greek generics segment, and his strategy for growth; both domestic and international. Can you please start by telling us how your originally came to found Alvion back in…

Taiwan JCP is home to over five decades of generic medication production and is a cornerstone household brand for numerous products in Taiwan’s domestic market, most notably with CNS medications. The company’s chairman and CEO, PH Huang details how they have gone about utilizing their post-IPO funds to enhance the company’s…

Poland Poland’s entrance into the EU has been a catalyst for growth that has allowed the country to flourish, shown by the nation’s ranking as the eighth largest economy in Europe according to the World Bank. The introduction into Europe has sprung the borders open, and for the Polish pharmaceutical industry this…

Taiwan Fangchen Lee, Chairman of YungShin Global Holding on strengthening the groups’s vertical integration, expanding product portfolio, and instilling a collaborative approach in the local generics industry, with the vision to build a Taiwan-based pharmaceutical entity that could be globally competitive. YungShin Global Holding proudly stands out as the largest domestic healthcare group of companies…

Europe Europe accounts for 22.2 percent of global pharma sales; more than Africa, Asia, Australasia, and Latin America combined, but less than half of North America. The biopharmaceutical industry is a key contributor to the European economy in terms of both trade surplus and employment; especially highly-skilled R&D jobs. Germany is…

Mexico M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican affiliate within the global strategy of the company. Could you introduce yourself to our international readers as well as the…

Mexico Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s footprint in Latin America by bringing more expertise and R&D resources. Could you please introduce yourself to our international audience…